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Abstract 
Our aim was to provide a systematic review of studies on the burden of disease due to second-hand 
smoke (SHS) exposure, reviewing methods, exposure assessment, diseases causally linked to SHS, 
health outcomes, and estimates available to date. 
A literature review of studies on the burden of disease from SHS exposure, available in PubMed and 
SCOPUS, published 2007-2018 in English language, was carried out following the PRISMA 
recommendations. Overall, 588 studies were first identified, and 94 were eligible. 
Seventy-two studies were included in the systematic review. Most of them were based on the 
comparative risk assessment approach, assessing SHS exposure using mainly surveys on exposure at 
home/workplaces. Diseases more frequently studied were: lung cancer, ischemic heart disease, stroke, 
chronic obstructive pulmonary disease, asthma and breast cancer in adults; lower respiratory tract 
infection, otitis media, asthma, sudden infant death syndrome and low birth weight in children. The 
SHS exposure assessment and the reported population attributable fractions (PAF) were largely 
heterogeneous. As an example, the PAF from lung cancer varied between 0.6% and 20.5%. Moreover, 
PAF were estimated applying relative risks and SHS exposures with no consistent definitions or with 
different age classes.  
The research gap on the SHS exposure burden is shrinking. However, estimates are not yet available for 
a number of countries, particularly the Middle Eastern and African countries, and not all diseases with 
the strongest evidence of causation, such as sudden infant death syndrome, have been explored. 
Moreover, in some cases the applied methodology revealed relatively low quality of data.  
 
 
 
Key-words: systematic review; second-hand smoke; burden of disease; population attributable fraction; 
tobacco
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Introduction 
Exposure to second-hand tobacco smoke (SHS) has been classified as a “Group 1” carcinogen (known 
human carcinogen) by the International Agency for Research on Cancer and has been shown to have 
several adverse health effects on adults and children, including respiratory outcomes, acute and chronic 
cardiovascular effects, and lung cancer.1-2  
Smoking bans have been increasingly applied all over the world after the recommendation of the World 
Health Organization (WHO) in 2007 to comply with Article 8 of the Framework Convention on 
Tobacco Control (FCTC).3 Smoke-free policies has been broadly applied in workplaces, public venues 
and transportation.4 Decreases in SHS exposure after the implementation of smoke-free policies was 
showed in several studies. with reductions up to 80–90% in workplaces and public places 5-7 
As a consequence, the social unacceptability of SHS and consequently the adoption of voluntary 
smoking bans in homes in the European Union (EU) countries increased.8 Evidence suggests that there 
has been an increase in the prevalence of smoke-free homes. For example, smoke-free homes increased 
from 72% in 2008 to 78% in 2012 in Italy, after 8 years from the ban implementation,9-10 and from 16% 
in 1998 to almost 50% in 2008 in smokers’ houses in England.11 Moreover, the percentage of Spanish 
households that reported expenditure on tobacco decreased by 2% after the Spanish ban of 2011.12 
Although population exposure to SHS has declined over the past two decades, many non-smokers are 
still exposed to SHS in workplaces, public places, homes, and vehicles. Worldwide, 40% of children, 
33% and 35% respectively of non-smoking males and females were exposed to SHS in 2004.13 Non-
smokers’ exposure to SHS has declined by 97% in the past 20 years in Scotland, but there are still 
nearly one in five non-smoking adults who have measurable exposure to SHS on any given day.14 
Moreover, 54% of youths are still exposed to SHS in any setting in Italy,15 exposure to SHS at home 
was the main source of exposure for non-smokers in Spain,16 and in 2016 72% of children under 12 
years are exposed in any setting in Spain.17 
In 2017, globally 1.2 million of deaths were attributable to SHS exposure, of which 63,822 occurred 
among children younger than 10 year-old.18 The largest number of estimated deaths attributable to SHS 
exposure in adults was caused by ischaemic heart disease (IHD), followed by lower respiratory 
infections (LRI) in children, and asthma in adults, whereas in terms of disability-adjusted life years 
(DALY) due to exposure to SHS, most DALYs were from LRI in children, followed by those from 
IHD and then from asthma in adults.13 Almost half of the total burden attributable to exposure to SHS 
was in Southeast Asia and in the Western Pacific, with a high burden of disease also estimated in 
Europe, particularly in the Eastern and Mediterranean countries.13 
There are several studies that have estimated the SHS-attributable burden at a global, national, or 
regional level. However, they used different approaches and methodologies, lists of diseases attributable 
to SHS exposure, SHS exposure assessments, and outcomes for estimating the burden. As a way to 
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provide a systematic information about the different approaches, the main aim of this systematic review 
is to describe and summarize the estimates available  between 01/01/2017 and 31/12/2018 of the SHS 
exposure and the health impact, in order to map the estimated disease burden and to identify data gaps.  
 
Methods 
We performed a systematic revision of the published literature of studies that estimated the burden of 
disease due to SHS exposure at the population level. Any study type providing estimates of mortality, 
morbidity or costs derived from direct counting, from special surveys, or from modelling was 
considered. We followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses 
(PRISMA) guidelines (see apprendix).19 For this purpose, systematic literature searches were conducted 
in PubMed (United States National Library of Medicine; http://www.pubmed.org) and SCOPUS 
(Elsevier; ). 
For SHS exposure we used the keywords “secondhand” or “second-hand” or “passive smok*” or 
“environmental tobacco”, and for its burden we searched for “burden” or “attributable”. We repeated 
the search in PubMed also using the Mesh term “Tobacco smoke pollution”. The search was limited to 
English language studies published between 01/01/2007 and 31/12/2018 on humans. We arbitrarly 
decided to start from 2007, but such a choice was informed, aimed to review recent data. In addition, 
we checked reference lists of the retrieved articles. The syntax for PubMed and Scupus searches is 
reported in the Appendix. 
We excluded editorials, statements of experts, reviews and other non-original researches, e.g., studies 
reporting and commenting data from other studies. Moreover, because they normally do not contain 
original estimates of attributable burden, we excluded studies that estimated the burden with a cost-
effectiveness design or studies that simulate the introduction of a smoking ban.  We also excluded 
cohort or case-control studies assessing the role of SHS exposure in the aetiology of selected diseases. 
We did not a priori exclude systematic reviews and meta-analyses or case-control studies that were 
mostly aimed at obtaining estimates of relative mortality or morbidity risks due to SHS exposure, as in 
some cases the estimated relative risks (RRs) were then used in the same article in order to obtain 
burden estimates.20-22 
We identified 844 studies (280 from PubMed and 564 from SCOPUS), 256 of which were duplicates. 
The PubMed search with the Mesh term for SHS produced similar results (262 papers). Screening of 
titles left 482 articles on burden due to SHS exposure. The PRISMA flow chart is reported in Figure 1.  
After reading the titles and abstracts, we rejected 388 papers: 35% of them were reviews, letters, notes 
or other studies not reporting original results; 21% estimated RRs of death/disease from selected SHS-
related diseases due to SHS exposure or RRs for the effects of selected policies; 14% reported results of 
surveys or cohort studies on the prevalence of SHS exposure or SHS-related diseases or expenditures; 
15% were not on SHS or did not estimate the burden; the other were excluded because they were 
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performed in animals or cells, ecologic studies, on methods to measure or model exposure, meta-
analyses on RRs, on policies evaluation.  
Moreover, we rigorously examined the reference lists of the included articles in order to find missed 
papers and we added other 4 articles,23-26 one which was published in 2006 but we considered it too 
relevant for not including it in the review. 24 
All the articles retrieved were reviewed by two of the authors of this review (GC and AL) and for the 
studies that were included in the systematic review information on the study characteristics were 
registered using a data extraction form. Information included geography, methodology and 
assumptions of the analysis, exposure assessment, diseases under study with the associated RR 
definitions, type of outcomes and main results. In case of any disagreement, they again reviewed the 
article together, and achieved a consensus. 
Ninety-four studies were identified, and 22 of them were excluded after reading the full text thoroughly 
because they were not estimating the burden of disease due to SHS exposure. 
 
Results 
Study geography: We included 72 studies in the review. Four of them were carried out within the Global 
Burden of Disease, Injuries and Risk Factors Study (GBD), a project coordinated by the Institute for 
Health Metrics and Evaluation (IHME) that provides a comprehensive assessment of risk factor 
exposure and attributable burden of disease.25-27,80 Besides the GBD studies that estimated the burden 
for almost all countries worldwide, 21 studies were implemented in EU, 16 in the US and Canada, 18 in 
China and in other Asian countries (Japan, Korea, Mongolia, Taiwan, and Vietnam), 7 in Oceania 
Countries (Australia, Indonesia, and New Zealand), and the remaining in Morocco, Israel, Norway and 
Switzerland (Table 1). 
Methodology: Most of the studies used the comparative risk assessment (CRA) methodology (Table 1), a 
comparable and transparent approach developed by the WHO to estimate the disease burden from 
several diverse risk factors.13,28-30 The CRA approach consists in the following steps: (1) estimate of 
exposure in a population; (2) select the more appropriate relative risk; and (3) estimate the population 
attributable fraction (PAF). The resulting PAF, estimated by sex, age and disease, or population group 
is then multiplied by the number of DALYs, deaths, cases or costs in each group and the overall PAF is 
estimated as a weighted with weights the proportions in each stratum.  
The estimates of the burden of disease have been developed using the above method, as well as with 
variations of it. Some studies applied the CRA approach using RRs or prevalence directly estimated 
within a survey or cohort 21,22,31-33 or used them to make projections of the burden.34 In other cases the 
PAFs published in other studies were applied to the study population-specific statistics.35-37  
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Five studies used approaches different from the CRA method: simulation models,38-40 future excess 
fractions approach, 41 and life table approach.42 
Diseases: The burden was estimated for adults in 61.1% of the studies, for children in 12.5% of the 
studies and for both in 26.4% of the studies (Table 2). In most cases, only diseases with strongest 
evidence of causation with SHS were analysed. In fact, the diseases mainly studied for adults were lung 
cancer (LC) (76.2%), IHD (54.0%), stroke (33.3%), asthma (23.8%), chronic obstructive pulmonary 
disease (COPD) (17.5%) and breast cancer (11.1%). In the 2017 GBD study also the burden from 
diabetes was estimated. In children, the burden from LRI was studied in 60.7% of the papers, otitis 
media (OM) and asthma in 53.6%, sudden infant death syndrome (SIDS) in 25.0%, and low birth 
weight (LBW) in 17.9% (Table 2). 
Some studies analysed the burden of disease with weak or uncertain evidence of a causal relationship 
with SHS exposure (17 studies). In adults, few studies evaluated the burden from cervical (1 study),35 
larynx and pharynx (1),41 and nasal sinus cancer (2),35,42 hypertension (1),43 peptic ulcer (1),43 tuberculosis 
(1),44 atopic diseases (1),45 and multiple sclerosis (1).46 In children, we found studies evaluating the 
burden from preterm delivery and spontaneous abortion (1),35 stillbirth(1)47, burns (1),35 atopic 
diseases(1),45 attention deficit hyperactivity disorder (3),48-50 learning disability (1),48 problem behaviours 
(1)51, meningitis (1),23 and respiratory diseases other than asthma (upper respiratory infections (1),27 
respiratory distress syndrome and respiratory conditions of newborns (2),49,53 respiratory syncytial virus 
bronchiolitis (2),35,53 and pneumonia (2) 31,54). 
Population attributable fraction: In Tables 3 and 4 we reported the estimated PAF respectively for adults 
and children for diseases with the strongest evidence of causation with SHS, i.e. LC, IHD, COPD, 
stroke, asthma and breast cancer in adults; and OM, SIDS, LRI asthma and LBW in children. When 
both the PAF for deaths and DALYs were estimated, only that for deaths was reported in the tables. 
When PAFs were not reported, if possible, we estimated them using the RR and the prevalence 
estimates reported in the paper. Only RR defined for dichotomous exposure, i.e. SHS exposed/not 
exposed, were used in the PAF computation, thus the PAF was not estimated when this was not 
available.55   
For each disease the PAF were highly heterogeneous among studies. In adults, the PAF from lung 
cancer for all ages varied from 0.6% for exposure in both genders to SHS at home in the European 
study by Vineis et al. 32 up to 50.9% for males exposed to SHS in Indonesia.56 The PAF from IHD 
varied between 1.4% in New Zealand and 13% in Chinese women; that from COPD varied between 
4.1% in the GBD 2017 worldwide estimate and 12.2% in women from Taiwan; that from stroke varied 
between 1.3% in New Zealand and 5.3% in Korean men; the PAF from asthma varied between 4.6% in 
USA and 38% in Chinese women; finally, the PAF from breast cancer varied between 1.9% and 27% 
(Table 3). In children the PAF estimates ranged between 0.9% and 22.4% for otitis media in USA, 
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6.7%-43.6% for SIDS, 2.0%-31.9% for lower respiratory infections, 0.8%-35% for asthma and 2.1%-
23.5% for low birth weight (Table 4).   
In most cases, in order to estimate the PAF, the included papers used the same meta-analytical RR 
along with estimates of prevalence to SHS exposure that did not generally coincide with the definition 
of exposure to SHS in the studies included in such meta-analyses (Tables 3-4).  
Exposure assessment: SHS exposure was mainly assessed through surveys (56 out of 72 studies) asking for 
self-reported SHS spousal exposure or exposure at home or workplace and, sometimes, in car or 
hospitality venues; in 5 studies SHS was cotinine-measured and in 8 it was modelled (Table 2).  
In the surveys, exposure in the house or in the workplace was assessed by asking if participants were 
ever 57-63, daily 46,64 or at least once per week 38,43,64-67 exposed to SHS. Household exposure was also 
assessed by asking whether smoking was allowed in the house 48-49,68 or, in some cases, whether living 
with a smoker 33,44, 69-70, or, for children, whether parents smoked.21,45  
In the 2017 GBD study, as well as in the Cao et al (2018) study,71 SHS exposure within the household 
was considered to exist when non-smoking members of a household reported being exposed to SHS 
from a smoking member of the same household. Surveys on both household composition and tobacco 
habits were used to estimate the joint probability of being a non-smoker and living with a smoker.72 
Country, year, age and sex-specific estimates were then used in a spatiotemporal Gaussian process 
regression model to estimate exposure for every country.18  
Assumptions: In computing the SHS attributable burden for adults, smokers are usually excluded from 
the analyses, since it is supposed that the large impact of active smoking may mask the more subtle 
health effects due to SHS, and the PAF is therefore applied to the total burden in non-smokers only.28 
The definition of non-smoker was not uniform among studies. In some cases only never smokers, i.e., 
lifelong non-smokers, were considered,46,53,66-67,72-73 whereas in other cases both former and never 
smokers 32,54,61,74-75 were included among non-smokers. The latter group was in some cases defined also 
as everyone excluding current smokers, i.e. daily or occasional smokers or those declaring to be current 
smokers,22,44,70, 52,76-77 or daily smokers.25-26 Moreover, in some studies non-smokers were more formally 
defined as anyone whose total amount of smoked cigarettes was less than 100 during their lifetime,78 or 
those who had stopped smoking or had not smoked 100 cigarettes in their lifetime.60  
Data sources: In almost all the studies, the burden was estimated for countries or regions using official 
statistics. Two studies applied the CRA methodology to data (prevalence, costs) from survey samples 
,43-44 Shin et al. 45 estimated and applied the PAF in a cohort, Simons et al. 79 applied the PAF to the 
incidence extracted from a review of Canadian studies, whereas the Royal College of Physicians 23 used 
the incidence data estimated from a cohort of UK children. The GBD studies used estimates of 
mortality and DALYs from a model in order to provide figures for every country. A Bayesian meta-
regression model (DisMod-MR) and a spatiotemporal Gaussian process regression model (ST-GPR) 
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were used to pool raw data from different sources, control and adjust for bias in data, and incorporate 
other types of information such as country-level covariates.18  
Outcomes: The SHS–attributable burden of disease was mainly studied in terms of mortality (55.6% of 
the studies), followed by morbidity (33.3%), DALYs (22.2%) and costs (18.1%). Some studies 
investigated also the burden from hospital admissions or years of potential life lost (Table 1).  
Sensitivity analyses: In several studies, a univariate sensitivity analysis, changing various inputs and 
assumptions of the main analysis one at time, was performed in order to evaluate the robustness of the 
estimates. Some studies tested the lower and upper limits of the RRs or SHS prevalence estimates 
13,27,40,44,54,57-59,64,49,69,52,76,80. Waters et al. 37, who used a simplified CRA approach using PAF estimated for 
other populations, tested the PAF’s ranges in a sensitivity analysis. Other sources of exposure to SHS 
were also explored, including exposure in cars, workplaces or during leisure time,54,59,66-67 or by 
evaluating both self-reported and estimated with biomarkers.39, 52,66-67  
Assumptions about the study population were also explored, by considering different populations at 
risk from SHS, i.e. never smokers only, never and former smokers, and never, former, and current 
smokers.54,59,66-67 
In some sensitivity analyses health outcomes with less robust evidence were included.54, 66-67 In one 
paper, also the effect of lag times from exposure to the onset of the disease was tested.80 
In studies examining the impact of policies on the SHS attributable burden, sensitivity analyses were 
performed applying the bounds of the effect of policies published in the literature were carried out.58 
Rehm et al. 81 carried out a sensitivity analysis on cost estimates. In studies using methods different 
from the CRA approach, other parameters where varied in a sensitivity analysis, i.e. the method for 
producing projections of cancer incidence rates in Carey et al. 41, or changing the assumptions regarding 
smoking initiation rates in Cavana et al. 40 or smoking prevalence.76 
 
Discussion 
Our review shows that many hazards due to SHS exposure are well known and morbidity and mortality 
attributable to SHS have been studied widely, yet there are many diseases and regions with no 
information. Beyond the GBD studies, the burden for EU countries was estimated in 29% of the 
selected studies. However, not all 28 EU Member States were covered, since estimates were available 
for Belgium, Denmark, Finland, France, Germany, Hungary, Italy, the Netherlands, Poland, Spain, 
Sweden and the UK, only, most of them only in adults, and not for all diseases, not including some 
with evidence of a causal relationship with SHS. Several studies were carried out also in Northern 
America (16 studies, 22%), Asian (18 studies, 25%), and Oceania countries (7 studies, 10%). Moreover, 
very little research has been done in Middle Eastern or African countries, with the burden from SHS 
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estimated only in single studies carried out in Israel and Morocco.70,82 A further assessment is therefore 
still needed. 
The CRA methodology was the most widely used and most studies estimated the burden from diseases 
with a strong causal relationship with SHS exposure. For some diseases, however, despite the evidence 
of causation with SHS exposure, e.g. SIDS, LBW, and asthma, the burden was not widely evaluated and 
this could be due to the lack of data. The most frequently studied diseases were LC, IHD, COPD and 
stroke for adults, and LRI and OM for children. Moreover, recently also breast cancer and diabetes 
were included among the diseases with a strong evidence of causation with SHS exposure.18  
Results showed a large heterogeneity in PAF and, as a consequence, in the SHS-attributable burden. 
This could be due to variations in prevalence across countries which have both different smoking 
habits and legislations in place (e.g. Europe versus China and other Asian countries). As an example, in 
Asian compared to EU countries, there is a greater gap in smoking prevalence by gender. In fact, men 
are more likely to smoke, whereas women are more likely to be exposed to SHS, and therefore SHS-
attributable burden is heavier above all in Asian women. There is thus clearly a high burden in Asian 
countries which need for greater awareness and increased regulatory frameworks. 
In less than 10% of studies there was an objective measurement of exposure to SHS, and self-reported 
exposure was the most widely used estimate, mainly assessed using surveys asking for household or 
workplace exposure or quantifying daily exposure. However, the definition of exposure was highly 
heterogeneous among studies. Exposure in cars or during leisure time was rarely explicitly considered, 
probably because the corresponding RR, necessary for the PAF estimate, were not simply available. 
Due to high costs in collecting measurements, i.e., cotinine in urine or saliva, future studies are unlikely 
to adopt objective measurements of SHS exposure. Self-reported SHS exposure is considered a low-
cost approach to obtain a sufficiently accurate information on SHS exposure and several studies were 
carried out to validate the use of SHS exposure assessment questions with cotinine measurements, 
resulting in moderate to good correlations.85-86 Recommended questions for studies assessing SHS have 
been defined, in order to meet reasonable standards for reliability and validity.85 
Few studies in estimating the PAF, used the same assessment of SHS exposure as that used in the RR 
definition. In the studies on adults, Park at al.57 and Rumrich et al.62 used SHS exposure at home or 
workplace in both RR and prevalence. Vineis et al. 32 used the same survey for the RR and the 
prevalence estimate. The study by Pandeya et al.83 generated a good approximation since it estimated 
the PAF by applying the RR estimated with exposure from spousal to a prevalence estimated from a 
survey asking if living with an ever smoker. In children, beyond the SHS assessment, in several studies 
also the age bands for the prevalence estimation was not the same as the one of the RR definition. The 
Royal college of Physicians 23 for OM used the same definition of exposure for RR and SHS prevalence 
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as children exposed to household smoking; Max et al. for SIDS and for LBW used the same definition 
of SHS prevalence as the one of RR, i.e. children exposed to maternal smoking during pregnancy.49,52 
In some studies, a model was used to estimate the number of deaths or DALYs or the SHS exposure 
not available from official statistics or surveys.25-27,71,73,84 This approach permits to estimate SHS 
exposure for all countries with lacking information, but has the drawback of producing estimates with a 
larger uncertainty. 
In the burden of disease estimation many sources of uncertainty are used, such as RR and prevalence 
data, and assumptions, so sensitivity analyses should be used to test the impact of these sources of 
uncertainty and to obtain an estimation of the size of uncertainty itself.11 In most of the studies the 
sensitivity analyses tested the impact of different assumptions in terms of RRs, SHS prevalence and 
exposure definition.13,27,39-40,44,49, 52,57-59,54,64,66-67,69,76,80 The inclusion of current smokers and former smokers 
in the sensitivity analyses for acute coronary syndrome is noteworthy, given that smokers and former 
smokers experienced nearly as much a reduction as non-smokers in disease-specific admissions after 
the smoking ban in public places and workplaces.84 
Limit of this study is that papers not in English language, proceedings of conferences, and grey 
literature were not included in the systematic review. However, our study has the strength that, to our 
knowledge, it is the first comprehensive review with systematic approach on the burden due to SHS 
exposure. 
Conclusion  
This systematic review highlighted that the burden of disease due to SHS exposure has been extensively 
studied worldwide, with a great variability in the burden of SHS-associated diseases across 
countries/regions, probably due to the different level of exposures, but many areas remain with 
insufficient evidence. Important, not all diseases with the strongest evidence of causation were assessed, 
and the CRA methodology has been applied to several but not all countries consistently. Furthermore, 
we identified relevant gaps in the quality of data, that should be addressed in future studies.    
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Figure labels: 
Figure 1 – PRISMA flow chart of publications (01/01/2007-31/12/2018) included in the systematic review. 
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Table 1 – Results of the literature review on studies from PubMed and SCOPUS on the burden of disease from SHS exposure, published between 01/01/2007 and 
31/12/2018 in English language. 
Study 
Assessment 
method 
Country Disease Method Burden indicator 
Adults 
Ádám et al., 2013 58 survey Hungary LC, IHD, COPD, stroke CRA deaths, DALYs 
Becher et al., 2018 64 survey Germany LC 
CRA with modified 
formula for the never 
smokers estimation 
deaths 
Cai et al., 2014 43 survey China 
COPD, asthma, IHD, stroke, 
hypertension, peptic ulcer 
CRA healthcare costs§* 
Cao et al., 2018 71 model France LC CRA cases 
Carey et al., 2017 41 survey Australia LC, larynx cancer, pharynx cancer 
projections using future 
excess fraction (FEF) 
deaths 
Cavana et al., 2008 40 - New Zeeland Overall 
simulated based 
approaches 
deaths 
Cui et al., 2016 87 survey China (Hubei Province) LC, IHD, stroke, LRI CRA deaths, DALYs 
Feigin et al., 2016 88 model 
Worldwide (188 
countries) 
Stroke CRA DALYs 
Fischer et al., 2016 38 survey Germany IHD, stroke, COPD 
simulated based 
approaches 
cases 
Gan et al., 2007 65 survey China LC, IHD CRA deaths, DALYs 
García-Esquinas et al., 2018 55 survey US 
all cancers; LC; colon, rectum and 
anum; pancreas 
mediation approaches for 
survival data (changes in 
mortality mediated by 
changes in SHS exposure) 
deaths 
Ginsberg et al., 2014 82 - Israel overall 
naive: proportion of PAF 
from USA 
deaths, hospitalization 
days, costs 
GBD 2015 Risk Factors 
Collaborators, and others, 2016 25 
model Worldwide LC, IHD, stroke, LRI CRA deaths, DALYs 
GBD 2016 Risk Factors 
Collaborators, and others, 2017 26 
model Worldwide 
LC, IHD, COPD, stroke, LRI, breast 
cancer, diabetes 
CRA deaths, DALYs 
Gram et al., 2016 22 survey Norway breast cancer cohort CRA cases 
Ha et al., 2011 78 survey Korea IHD CRA deaths 
Hänninen et al., 2014 80 survey 
EU (Belgium, Finland, 
France, Germany, Italy, 
LC, IHD, asthma CRA DALY 
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the Netherlands) 
Hauri et al., 2011 42 survey Switzerland 
LC, IHD, stroke, nasal sinus cancer, 
COPD, asthma 
difference expected - 
observed number of 
hospital days, life table 
method for YLL 
hospital days, YLL 
Hedström et al., 2016 46 survey Sweden multiple sclerosis excess proportion of cases cases 
Heidrich et al., 2007 59 survey Germany IHD CRA deaths, cases 
Heo et al., 2015 60 survey Korea LC, IHD, asthma, COPD, stroke CRA deaths 
Heuschmann et al., 2007 61 survey Germany stroke CRA deaths, cases 
Hill et al., 2017 34 model Mongolia LC, IHD, stroke, COPD CRA projections deaths 
Islami et al., 2017 73 survey China LC CRA deaths 
Islami et al., 2018 74 cotinine-measured US LC CRA deaths, cases 
Järvholm et al., 2013 89 survey Sweden LC, acute myocardial infarction CRA deaths 
Lightwood et al., 2009 39 cotinine-measured US IHD 
simulated based 
approaches 
deaths, cases, healthcare 
costs§ 
Lim et al., 2012 27 model worldwide LC, IHD, stroke CRA deaths, DALYs 
Liu et al., 2014 75 survey 
US (Minnesota and the 
US) 
LC, IHD, asthma CRA, Lifetime excess risk deaths, asthma initiation 
López et al., 2007 66 survey Spain LC, IHD CRA deaths 
López et al., 2016 67 survey Spain LC, IHD CRA deaths 
Mason et al., 2016 54 survey New Zealand LC, IHD, stroke CRA deaths, DALYS  
Mason et al., 2015 53 cotinine-measured US (public housing in US) LC, IHD, asthma CRA cases, deaths, costs 
Max et al., 2012 52 
survey & cotinine-
measured 
US LC, IHD CRA 
deaths, YPLL, 
productivity 
Max et al., 2015 49 survey US LC, IHD, breast cancer, asthma CRA YPLL, deaths, costs 
Öberg et al., 2011 13 survey worldwide LC, IHD, asthma CRA deaths, DALYs 
Pandeya et al., 2015 83 model Australia LC CRA cases 
Park et al., 2014 57 survey Korea LC CRA deaths, cases 
Parkin, 2011 72 model UK LC CRA cases 
Permitasari et al., 2018 56 survey Indonesia LC CRA DALYs 
Plescia et al., 2011 36 - US (North Carolina) LC, stroke simplified CRA‡ treated prevalence, costs 
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Rehm et al., 2007 81 survey Canada cancer, cardiovascular disease CRA deaths, PLL, costs 
Rumrich et al., 2015 62 survey Finland asthma CRA 
prevalent cases, YLD, 
DALY 
Rushton et al., 2010 90 survey UK LC CRA cases 
Rushton et al., 2008 91 survey UK LC CRA deaths 
Rushton et al., 2012 92 survey UK LC CRA cases 
Saywell et al., 2013 35 - US (Indiana) 
LC, IHD, stroke, nasal sinus cancer, 
breast cancer, cervical cancer, asthma 
simplified CRA‡ 
loss-of-life and 
healthcare costs§ 
Schram-Bijkerk et al., 2013 63 survey The Netherlands LC, IHD, asthma CRA cases, DALYs 
Shin et al., 2017 45 survey New Zealand atopic diseases PAF in cohort PAF 
Sung et al., 2014 76 survey Taiwan 
LC, IHD, cerebrovascular disease,, 
asthma 
CRA 
deaths, YPLL, healthcare 
costs§ 
Tachfouti et al., 2016 70 survey Morocco LC, IHD CRA deaths 
The Smoke Free Partnership, 
2006 24 
survey EU (25 countries) LC, IHD, stroke, COPD CRA deaths 
Vineis et al., 2007 32 survey 
EU (France, Italy, 
Denmark, Sweden, The 
Netherlands and 
Potsdam, Germany) 
LC survey CRA cases 
Wang et al., 2011 93 survey China LC CRA deaths, cases 
Waters et al., 2009 37 - US (Minnesota) LC, stroke simplified CRA‡ 
cases, treated prevalence, 
costs 
Wilson et al., 2018 69 survey Australia cancer  deaths 
Wu et al., 2010 33 survey Taiwan (Kaohsiung City) COPD, chronic bronchitis survey CRA  
Xia et al., 2018 94 survey China LC CRA deaths 
Yao et al., 2015 44 survey China 
asthma, breast cancer, IHD, LC, 
tuberculosis 
CRA healthcare costs§ 
Yao et al., 2018 95 survey home US healthcare utilization Poisson model 
Zahra et al., 2016 77 survey Korea LC, IHD, stroke CRA DALYs 
Zahra et al., 2018 96 survey Korea LC, IHD, stroke CRA DALYs 
Children 
Behm et al., 2012 20 survey US SIDS CRA deaths 
Cui et al., 2016 87 survey China (Hubei Province) LRI, OM CRA deaths, DALYs 
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Ginsberg et al., 2014 82 - Israel overall 
naive: proportion of PAF 
from USA 
deaths, hospitalization 
days, costs 
GBD 2015 Risk Factors 
Collaborators, and others, 2016 25 
model Worldwide LRI, OM CRA deaths, DALYs 
GBD 2016 Risk Factors 
Collaborators, and others, 2017 26 
model Worldwide LRI, OM CRA deaths, DALYs 
Hänninen et al., 2014 80 survey 
EU (Belgium, Finland, 
France, Germany, Italy, 
the Netherlands) 
LRI, OM, asthma CRA DALY 
Hill et al., 2017 34 model Mongolia LRI CRA projections deaths 
Jarosińska et al., 2014 97 survey Poland LBW, SIDS, LRI, OM, asthma CRA cases,  DALYs 
Kabir et al., 2011 48 survey US 
learning disability, attention-deficit 
disorder, attention-
deficit/hyperactivity disorder, 
conductor behavioral disorders 
CRA cases 
Lim et al., 2012 27 model worldwide LRI, upper respiratory infections, OM CRA deaths, DALYs 
Mason et al., 2016 54 survey New Zealand 
LBW, SIDS, LRI, OM, pneumonia, 
asthma 
CRA deaths, DALYs 
Mason et al., 2015 53 cotinine-measured US (public housing in US) 
LBW, SIDS, LRI, respiratory syncytial 
virus bronchiolitis, OM, asthma 
CRA cases, deaths, costs 
Max et al., 2014 50 
survey & cotinine-
measured 
US (California) attention deficit hyperactivity disorder CRA 
education and healthcare 
costs§ 
Max et al., 2012 52 
survey & cotinine-
measured 
US 
SIDS, LBW, respiratory distress 
syndrome, other respiratory 
conditions of newborns 
CRA 
deaths, YPLL, 
productivity 
Max et al., 2015 49 survey US 
SIDS, LBW, LRI, OM, chronic 
respiratory symptoms, attention 
deficit hyperactivity disorder, asthma, 
respiratory distress syndrome, 
respiratory conditions of newborn 
CRA YPLL, deaths, costs 
Öberg et al., 2011 13 survey worldwide LRI, OM, asthma CRA deaths, DALYs 
Plescia et al., 2011 36 - US (North Carolina) LBW, LRI, OM, asthma and wheeze simplified CRA‡ treated prevalence, costs 
Reece et al., 2018 47 survey 
30 low-income and 
middle- income countries 
steelbirth CRA deaths 
Royal College of Physicians, 2010 
23 
survey UK LRI, wheeze, OM, asthma, meningitis CRA deaths, cases 
Rumrich et al., 2015 62 survey Finland asthma CRA 
prevalent cases, YLD, 
DALY 
Saywell et al., 2013 35 - US (Indiana) 
SIDS, asthma, respiratory syncytial 
virus bronchiolitis, OM, LRI, burns, 
simplified CRA‡ 
loss-of-life and 
healthcare costs§ 
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LBW, spontaneous abortion 
Schram-Bijkerk et al., 2013 63 survey The Netherlands SIDS, LRI, OM, asthma CRA cases, DALYs 
Shin et al., 2017 45 survey New Zeland atopic diseases PAF in cohort PAF 
Simons et al., 2011 79 survey Canada asthma CRA cases 
Suzuki et al., 2009 31 survey 
Vietnam (Khanh Hoa 
Province) 
pneumonia survey CRA hospital admissions 
Tabuchi et al., 2015 21 survey Japan asthma CRA with estimated RR hospitalization 
Waters et al., 2009 37 - US (Minnesota) LRI, LBW, OM, asthma and wheeze simplified CRA‡ 
cases, treated prevalence, 
costs 
Yang et al., 2018 51 survey Korea problem behaviors CRA cases 
LC: lung cancer; IHD: ischemic heart disease; LBW: low birth weight; SIDS: sudden infant death syndrome; LRI: lower respiratory tract infection; OM: otitis media; 
COPD: chronic obstructive pulmonary disease; CRA: comparative risk assessment; YPLL: years of potential life lost; DALY: disability adjusted life year; YLD: years 
lived with disability. 
§ Healthcare costs: expenditures for inpatient hospital stays and outpatient visits. 
* based on survey information on prevalence, costs, rural southwest in China. 
‡ PAF form published studies.  
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Table 2 - Summary of the literature review on studies from PubMed and SCOPUS on the burden of disease from SHS exposure, published between 01/01/2007 and 
31/12/2018 in English language. 
Summary of measure Number of studies (total N=72) 
N (%) 
Outcomes 
   mortality 40 (55.6) 
   morbidity 24 (33.3) 
   costs 13 (18.1) 
   DALYs 16 (22.2) 
   YPLL/hospitalization days/admissions 9 (12.5) 
Population 
   adults 44 (61.1) 
   children 9 (12.5) 
   both 19 (26.4) 
Diseases 
Adults (total N=63) 
       LC 48 (76.2) 
       IHD 34 (54.0) 
       COPD 11 (17.5) 
       stroke 21 (33.3) 
       asthma 15 (23.8) 
       breast cancer 7 (11.1) 
       diabetes 1 (1.6) 
Children (total N=28) 
       LRI 17 (60.7) 
       OM 15 (53.6) 
       SIDS 7 (25.0) 
       asthma  15 (53.6) 
       LBW 5 (17.9) 
Exposure assessment 
   survey  questionnaire 54 (75.0) 
   cotinine-measurement 3 (4.2) 
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   survey  questionnaire & cotinine-measurement 2 (2.8) 
   model 8 (11.1) 
   not reported 5 (6.9) 
DALY: disability adjusted life year; YPLL: years of potential life lost; LC: lung cancer; IHD: ischemic heart disease; COPD: chronic obstructive pulmonary disease; 
LRI: lower respiratory tract infection; OM: otitis media; SIDS: sudden infant death syndrome; LBW: low birth weigh 
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Table 3 – Proportion attributable fraction (PAF) estimates due to second-hand smoke (SHS) among 
adults never (or non-) smokers for selected diseases, sorted by disease, continent (world, North 
America, Oceania, Europe, Asia and Africa), year of publication and author name. 
Study 
Country 
RR SHS exposure PAF 
(%) 
Notes 
Definition Endpoint* Source RR^ Definition Source % 
 
Lung cancer 
 
World 
Öberg et al., 
2011 13 
World 
NA Inc/Mort 2 H: 1·21 
Wo: 1·22 
At home or at 
work 
  1.8 (DALYs) Only PAF for 
DALYs was 
provided. 
GBD, 2016 25 
World 
NA NA Integrated 
exposure 
response 
curves (IER) 
were used to 
estimate 
country-
specific RR. 
NA SHS exposure in 
non-smokers. 
Exposure by a 
household 
member. 
Various 
national and 
international 
surveys. 
NA 1.7  
GBD, 2017 26 
World 
NA NA IER for 
PM2.5 air 
pollution 
were used to 
estimate 
country-
specific RR. 
NA SHS exposure in 
non-smokers. 
Exposure by a 
household 
member. 
NA NA 1.6  
North America 
Waters et al., 
2009 37 
USA 
NA NA 2 NA NA National 
survey from 
Minnesota 
Department of 
Health 
NA 4.9 Non-original. PAF 
from 98-99 
Liu et al., 
2014 75 
USA 
NA NA 2 1.22 SHS exposure in 
non-smokers. 
Serum cotinine 
level ≥0.05 
ng/mL. 
National 
Health and 
Nutrition 
Examination 
Survey 
(NHANES)100 
Men:           51.9 
Women:      44.2 
Total:          9.5 PAF for 
Minnesota only are 
also available 
Mason et al., 
2015 53 
USA 
Exposure to SHS 
from the spouse 
Inc 2 1.21 SHS exposure in 
non-smokers. 
Scenario 1: 
serum cotinine 
level ≥0.05 
ng/mL. 
Scenario 2: 
serum cotinine 
level ≥0.015 
ng/mL. 
NHANES Scenario 1 
 18-50 y:        48 
 51-64 y:        46 
 65-84 y:        38 
 ≥85 y:           38 
Scenario 2 
 18-50 y:        81 
 51-64 y:        79 
 65-84 y:        75 
 ≥85 y:           75 
Scenario 1 
 18-50 y:        9 
 51-64 y:        9 
 65-84 y:        7 
 ≥85 y:           7 
Scenario 2 
 18-50 y:      15 
 51-64 y:      14 
 65-84 y:      14 
 ≥85 y:         14 
 
Max et al., 
2015 49 
USA 
Spousal ever 
smoking 
Inc/Mort 101 1.29 SHS exposure in 
non-smokers. 
Living in a house 
where someone 
smokes inside at 
least 1 day per 
week. 
California 
Health 
Interview 
Survey (CHIS) 
5.0 1.4  
Islami et al., 
2018 74 
USA 
Spousal ever 
smoking 
Inc 52,102 1.29 SHS exposure in 
non-smokers. 
Serum cotinine 
level ≥0.05 
ng/mL. 
NHANES 103 Men:           32.8 
Women:      22.9 
Cases 
 Total:         2.7 
 Men:          3.1 
 Women:    2.3 
Deaths 
 Total:         2.8 
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 Men:          3.2 
 Women:    2.3 
Oceania 
Pandeya et 
al., 2015 83 
Australia 
Spousal smoking Inc/Mort 104  M: 1.37 
W: 1.24 
SHS exposure in 
never. Living 
with an ever 
smoker. 
Data from 
population 
census 105 
Men:              17 
Women:        25 
Total:          6.4 
Men:           6.1 
Women:     6.7 
 
Mason et al., 
2016 54 
New Zealand 
Exposure to SHS 
from the spouse 
Inc 2 1.21 SHS exposure in 
non-smokers. 
People smoking 
inside the 
respondent’s 
home and/or in 
the car they 
travelled in. 
New Zealand 
Health Surveys 
5.4 1.1 PAFs estimated by 
us from RR and % 
SHS exposure. 
Permitasari et 
al., 2018 56 
Indonesia 
NA NA 105 M: 2.28 
W: 1.31 
NA  NA  Men:                81 
Women:           75 
Men:            50.90 
Women:      18.86 
Prevalence of SHS 
estimated by us 
inversely by RR 
and PAF. 
Europe 
López et al., 
2007 66 
Spain 
Spousal smoking Inc/Mort 106 HM: 1.34 
HW: 1.24 
Wo: 1.39 
H&Wo: 1.39 
SHS exposure in 
never smokers. 
At least one hour 
per week at 
home and/or at 
work.  
Regional 
surveys in 
Spain 107-109 
At home only 
 Men 
  35-64 y:    22.6 
  ≥65 y:       28.6 
 Women 
  35-64 y:    33.0 
  ≥65 y:       30.8 
At work only 
 Men 
  35-64 y:    35.9 
Women 
  35-64 y:    19.3 
At home and work 
 Men 
  35-64 y:      9.5 
Women 
  35-64 y:    12.0 
At home only 
 Men 
  35-64 y:    7.1 
  ≥65 y:       8.9 
 Women 
  35-64 y:    7.3 
  ≥65 y:       6.9 
At work only 
 Men 
  35-64 y:  12.3 
Women 
  35-64 y:    7.0 
At home and work 
 Men 
  35-64 y:    3.6 
Women 
  35-64 y:    4.5 
Some PAFs 
estimated by us 
from RR and % 
SHS exposure. 
Vineis et al., 
2007 32 
Europe 
Present exposure 
at home and/or 
woprkplace. 
Inc/Mort EPIC study 
110-111 
H: 1.03 
Wo: 1.65 
H&Wo: 1.34 
SHS exposure 
among non-
smokers. Present 
exposure at 
home and/or 
woprkplace. 
EPIC study 110-
111 
Home:            19 
Work:             47 
Home and/or work:              
58 
Home:        0.6 
Work:          24 
Home and/or 
work:           16 
 
Parkin, 2011 72  
UK 
SHS exposure 
from spouse/at 
workplace 
NA 104 M: 1.37 
W: 1.24 
  Men:              17 
Women:         23 
Men:           5.9 
Women:     5.2 
PAFs estimated by 
us from RR and % 
SHS exposure. 
Järvholm et 
al., 2013 89 
Sweden 
NA NA NA 1.25 SHS exposure in 
non-smoking 
women. 
112 Women:        5.0 Women:     1.2  
Schram-
Bijkerk et al., 
2013 63 
The 
Netherlands 
NA NA 102 1.21 SHS exposure in 
non-smokers. 
Daily exposure. 
113 18-40 (mean: 29) 5.7  
López et al., 
2016 67 
Spain 
Spousal smoking; 
workplace 
exposure 
Inc/Mort  106 HM: 1.34 
HW: 1.24 
Wo: 1.39 
H&Wo: 1.39 
SHS exposure in 
never smokers. 
One or more 
people usually 
smoking inside 
the home; a 
workpartner 
usually smoke 
Representative 
national survey 
At home only 
 Men 
  35-64 y:      9.4 
  ≥65 y:       10.0 
 Women 
  35-64 y:      9.0 
  ≥65 y:         9.8 
At work only 
At home only 
 Men 
  35-64 y:    3.1 
  ≥65 y:       3.3 
 Women 
  35-64 y:    2.1 
  ≥65 y:       2.3 
At work only 
For PAF 
computation, we 
used RR estimates 
from 66 
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close enough to 
smell the SHS. 
 Men 
  35-64 y:      8.1 
Women 
  35-64 y:      4.9 
At home and work 
 Men 
  35-64 y:      1.7 
Women 
  35-64 y:      0.4 
 Men 
  35-64 y:    3.1 
Women 
  35-64 y:    1.9 
At home and work 
 Men 
  35-64 y:    0.7 
Women 
  35-64 y:    0.2 
Becher et al., 
2018 64 
Germany 
SHS exposure at 
home; spousal 
smoking 
Inc/Mort  Pooled 
estimate 
from 2,114 
1.21 SHS exposure in 
never smokers. 
At any place, 
once per week or 
daily 
Own estimate 
from available 
data 115 
Men:           39.5 
Women:      23.5 
Men:         7.7 
Women:   4.7 
 
Cao et al. 
2018 71 
France 
never smokers 
who were exposed 
to tobacco smoke 
from a smoking 
partner 
incidence 104 M: 1.37 
W: 1.24 
SHS exposure in 
never on-
smokers. 
Exposure by a 
household 
member ^ 
National 
Surveys 
(INSEE on for 
marital status, 
Baromètre 
santé on for 
smoking 
status) 
Men 
30-34 y:     35.3 
35-39 y:     37.5 
40-44 y:     37.2 
45-49 y:     39.7 
50-54 y:     37.9 
55-59 y:     32.9 
60-64 y:     28.4 
65-69 y:     18.0 
70-74 y:     15.7 
75-79 y:     11.1 
80-84 y:     10.5 
≥85y:     10.5 
Women 
30-34 y:    41.7 
35-39 y:    44.1 
40-44 y:     45.2 
45-49 y:     50.9 
50-54 y:     50.3 
55-59 y:     56.2 
60-64 y:     57.6 
65-69 y:     62.1 
70-74y:     59.6 
75-79  y:     62.4 
80-84 y:     56.4 
≥85 y:     56.4 
Men:            4.2   
Women:       6.7 
 
Asia 
Wang et al., 
2011 93 
China 
Ever exposure 
from spouse or 
ever workplace 
exposure 
Mort 116 H: 1.15 
Wo: 1.79 
SHS exposure in 
never smokers. 
At home and 
workplace. 
National 
survey 
Women 
 Home:        36.7 
 Workplace:  8.4 
11.1 They report PAF 
for at home and 
workplace 
combined 
Heo et al., 
2015 60 
Korea 
Spousal ever 
smoking 
Inc 101-102,104 1.29 SHS exposure in 
non-smokers. 
KNHANES 
Household 
member 
smoking at home 
and/or smell of 
tobacco smoke 
at workplace. 
KCHS 
At least 1 hour 
of exposure at 
home and/or 
smell of smoke 
for at least 1 
hour per day at 
workplace. 
Korean 
National 
Health and 
Nutrition 
Examination 
Survey 
(KNHANES) 
2005-2010 117; 
Korean 
Community 
Health 
Survey 
(KCHS) 118  
Men:           22.2 
Women:      19.9 
Men:           6.0 
Women:     5.5 
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2014 57 
Korea 
home/at 
workplace 
conducted by 
the authors 
HM: 1.00 
HW: 1.32 
WoM: 1.15 
WoW: 1.37 
 
MORT 
HM: 1.34 
HW: 1.32 
WoM: 1.15 
WoW: 1.37 
non-smokers. At 
home or 
workplace. 
117  Men:          14.8 
 Women:     60.1 
At workplace only 
 Men:          42.2 
 Women:    14.7 
 
At home only 
 Men:             - 
 Women:  16.3 
At workplace only 
 Men:          5.9 
 Women:    5.2 
At home or 
workplace 
 Men:          5.9 
 Women:  20.7 
 
MORTALITY 
At home only 
 Men:          4.8 
 Women:  16.1 
At workplace only 
 Men:          5.9 
 Women:    5.2 
At home or 
workplace 
 Men:        10.5 
 Women:  20.5 
Sung et al., 
2014 76 
Taiwan 
Spousal ever 
smoking 
Inc 101 1.29 SHS exposure in 
non-smokers. 
Exposure at 
home or at 
workplace during 
the past week. 
National 
survey (Adult 
Smoking 
Behavior 
Survey) 
Total:          24.7 
Men:           24.1 
Woman:     25.2 
Total:          6.7 
Men:           6.5 
Women:     6.8 
PAFs estimated by 
us from RR and % 
SHS exposure. 
Yao et al., 
2015 44 
China 
NA NA 119 1.13 Participants 
living with a 
current smoker. 
National Rural 
Household 
Survey 
(NRHS) 
Men:           35.0 
Women:      62.2 
Men:             4 
Women:        7 
 
Zahra et al., 
2016 77 
Korea 
NA NA 120 1.51 SHS exposure in 
non-smokers. At 
home or 
workplace. 
KNHANES 
117 
Men 
 25-29 y:     41.7 
 30-34 y:     59.0 
 35-39 y:     56.4 
 40-44 y:     66.0 
 45-49 y:     59.0 
 50-54 y:     53.3 
 55-59 y:     53.5 
 60-64 y:     37.4 
 65-69 y:     27.5 
 70-74 y:     16.3 
 75-79 y:     17.9 
 ≥80 y:          5.2 
Women 
 25-29 y:     42.5 
 30-34 y:     23.3 
 35-39 y:     30.0 
 40-44 y:     30.0 
 45-49 y:     34.2 
 50-54 y:     34.3 
 55-59 y:     33.1 
 60-64 y:     23.2 
 65-69 y:     14.9 
 70-74 y:     16.2 
 75-79 y:       8.5 
 ≥80 y:          4.4 
Men 
 25-29 y:      17 
 30-34 y:      23 
 35-39 y:      22 
 40-44 y:      25 
 45-49 y:      23 
 50-54 y:      21 
 55-59 y:      21 
 60-64 y:      16 
 65-69 y:      12 
 70-74 y:        8 
 75-79 y:        8 
 ≥80 y:           3 
Women 
 25-29 y:      18 
 30-34 y:      11 
 35-39 y:      13 
 40-44 y:      13 
 45-49 y:      15 
 50-54 y:      15 
 55-59 y:      14 
 60-64 y:      11 
 65-69 y:        7 
 70-74 y:        8 
 75-79 y:        4 
 ≥80 y:           2 
 
Islami et al., 
2017 73 
China 
NA NA 121 M: 1.58 
W: 1.34 
 
SHS exposure in 
never smokers. 
At least weekly 
either at home or 
at work. 
Global Adult 
Tobacco 
Survey 100 
NA Total:          8.9 
Men:           3.0 
Women:   21.3 
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Zahra and 
Park, 2018 96 
Korea 
NA NA 120 1.51 SHS exposure in 
nonsmokers at 
work or home 
KCHS118 6-35 9.40 PAFs estimated by 
us from RR and % 
SHS exposure 
(mean prevalence: 
20.5%). 
Xia et al., 
2018 94 
China 
NA NA NA NA SHS exposure in 
non-smokers for 
at least 15 min 
on 1 day per 
week 
2002 Chinese 
National 
Nutrition and 
Health Survey 
(NNHS) 
Men:             25.35 
Women:        46.0 
 Men:             5.9 
Women:        11.5 
  
Africa 
Tachfouti et 
al., 2016 70 
Morocco 
Spousal smoking Inc/Mort 106 HM: 1.34 
HW: 1.24 
Wo: 1.39 
H&Wo: 1.39 
SHS exposure in 
never smokers. 
At home or at 
workplace. 
National 
survey 122 
At home only 
 Men 
  35-64 y:    20.0 
  ≥65 y:       15.1 
 Women 
  35-64 y:    38.4 
  ≥65 y:       25.0 
At work only 
 Men 
  35-64 y:    57.4 
Women 
  35-64 y:    25.5 
At home and work 
 Men 
  35-64 y:    25.3 
Women 
  35-64 y:    17.7 
At home only 
 Men 
  35-64 y:    6.4 
  ≥65 y:       4.9 
 Women 
  35-64 y:    8.4 
  ≥65 y:       5.6 
At work only 
 Men 
  35-64 y:  18.3 
Women 
  35-64 y:    9.0 
At home and work 
 Men 
  35-64 y:    9.0 
Women 
  35-64 y:    6.5 
Some PAFs 
estimated by us 
from RR and % 
SHS exposure. 
 
Ischemic heart disease (IHD) 
 
World 
Öberg et al., 
2011 13 
World 
 Inc 2 1.27 SHS exposure in 
non-smokers. 
Exposure at 
home or at work. 
  4.5 (DALYs) Only PAF for 
DALYs was 
provided. 
GBD, 2016 25 
World 
NA NA IER curves 
were used to 
estimate 
country-
specific RRs. 
NA SHS exposure in 
non-smokers. 
Exposure by a 
household 
member. 
Various 
national and 
international 
surveys. 
NA 4.3 
 
 
GBD, 2017 26 
World 
NA NA IER curves 
for PM2.5 air 
pollution 
were used to 
estimate 
country-
specific RRs. 
NA SHS exposure in 
non-smokers. 
Exposure by a 
household 
member. 
NA NA 3.5  
North America 
Liu et al., 
2014 75 
USA 
NA NA 2 1.27 SHS exposure in 
non-smokers. 
Serum cotinine 
level ≥0.05 
ng/mL. 
NHANES 100 Men:           51.9 
Women:      44.2 
Total:        11.4 PAF for 
Minnesota only are 
also available 
Mason et al., 
2015 53 
USA 
SHS exposure at 
home by a spouse 
or cohabitant or at 
workplace 
Inc/Mort 2,13 1.27 SHS exposure in 
non-smokers. 
Scenario 1: 
serum cotinine 
level ≥0.05 
ng/mL. 
Scenario 2: 
serum cotinine 
NHANES Scenario 1 
 51-64 y:        46 
 65-84 y:        38 
 ≥85 y:          38 
Scenario 2 
 51-64 y:        79 
 65-84 y:        75 
 ≥85 y:          75 
Scenario 1 
 51-64 y:      11 
 65-84 y:        9 
 ≥85 y:           9 
Scenario 2 
 51-64 y:      18 
 65-84 y:      17 
 ≥85 y:         17 
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level ≥0.015 
ng/mL. 
Max et al., 
2015 49 
USA 
NA Inc 2 1.50 SHS exposure in 
non-smokers. 
Living in a house 
where someone 
smokes inside at 
least 1 day per 
week. 
CHIS 5.01 2.4  
Oceania 
Mason et al., 
2016 54 
New Zealand 
SHS exposure at 
home by a spouse 
or cohabitant or at 
workplace 
Inc/Mort 2 1.27 SHS exposure in 
non-smokers. 
People smoking 
inside the 
respondent’s 
home and/or in 
the car they 
travelled in. 
New Zealand 
Health Surveys 
5.4 1.4 PAFs estimated by 
us from RR and % 
SHS exposure. 
Europe 
López et al., 
2007 66 
Spain 
NA NA 123-124 H: 1.30 
Wo: 1.21 
H&Wo: 1.30 
SHS exposure in 
never smokers. 
At least one hour 
per week at 
home and/or at 
work.  
Regional 
surveys in 
Spain 107-109 
At home only 
 Men 
  35-64 y:    22.6 
  ≥65 y:       28.6 
 Women 
  35-64 y:    33.0 
  ≥65 y:       30.8 
At work only 
 Men 
  35-64 y:    35.9 
Women 
  35-64 y:    19.3 
At home and work 
 Men 
  35-64 y:      9.5 
Women 
  35-64 y:    12.0 
At home only 
 Men 
  35-64 y:    6.3 
  ≥65 y:       7.9 
 Women 
  35-64 y:    9.0 
  ≥65 y:       8.5 
At work only 
 Men 
  35-64 y:    7.0 
Women 
  35-64 y:    3.9 
At home and work 
 Men 
  35-64 y:    2.8 
Women 
  35-64 y:    3.5 
Some PAFs 
estimated by us 
from RR and % 
SHS exposure. 
Schram-
Bijkerk et al., 
2013 63 
The 
Netherlands 
SHS exposure at 
home by a spouse 
or cohabitant or at 
workplace 
Inc/Mort 2 1.27 SHS exposure in 
non-smokers. 
Daily exposure. 
113 18-40 (mean: 29) 7.3  
Fischer et al., 
2016 38 
Germany 
Mixed definitions 
(regular SHS 
exposure; e.g., 
spousal smoking 
or exposure to 20 
cigs/day) 
Inc/Mort 125 M: 1.06 
W: 1.50  
SHS exposure 
likely in non-
smokers. At any 
place, once per 
week or daily 
Own estimate 
from available 
data 126 
Men 
 18-29 y:     72.0 
 30-39 y:     49.0 
 40-49 y:     46.4 
 50-59 y:     42.5 
 60-69 y:     27.0 
 ≥70 y:        16.2 
Women 
 18-29 y:     61.6 
 30-39 y:     27.0 
 40-49 y:     28.1 
 50-59 y:     24.8 
 60-69 y:     17.0 
 ≥70 y:          8.9 
Men 
 18-29 y:     4.1 
 30-39 y:     2.9 
 40-49 y:     2.7 
 50-59 y:     2.5 
 60-69 y:     1.6 
 ≥70 y:        1.0 
Women 
 18-29 y:   23.5 
 30-39 y:   11.9 
 40-49 y:   12.3 
 50-59 y:   11.0 
 60-69 y:     7.8 
 ≥70 y:        4.3 
PAFs estimated by 
us from RR and % 
SHS exposure 
López et al., 
2016 67  
Spain 
NA NA 123-124 H: 1.30 
Wo: 1.21 
H&Wo: 1.30 
SHS exposure in 
never smokers. 
One or more 
people usually 
smoking inside 
the home; a 
workpartner 
usually smoke 
Representative 
national survey 
At home only 
 Men 
  35-64 y:      9.4 
  ≥65 y:       10.0 
 Women 
  35-64 y:      9.0 
  ≥65 y:         9.8 
At work only 
At home only 
 Men 
  35-64 y:    2.7 
  ≥65 y:       2.9 
 Women 
  35-64 y:    2.6 
  ≥65 y:       2.9 
At work only 
For PAF 
computation, we 
used RR estimates 
from 66. 
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close enough to 
smell the SHS. 
 Men 
  35-64 y:      8.1 
Women 
  35-64 y:      4.9 
At home and work 
 Men 
  35-64 y:      1.7 
Women 
  35-64 y:      0.4 
 Men 
  35-64 y:    1.7 
Women 
  35-64 y:    1.0 
At home and work 
 Men 
  35-64 y:    0.5 
Women 
  35-64 y:    0.1 
Asia 
Ha et al., 2011 
78 
Korea 
SHS exposure at 
workplace 
Inc/Mort Meta-analysis 
conducted by 
the authors 
M: 1.19 
W: 1.22 
SHS exposure in 
never smokers. 
At work for 
more than ¼ of 
working time (2 
hours a day) 
National 
survey on 
working 
conditions 127 
Men:           19.0 
Women:      11.3 
Men:         3.48 
Women:   2.43 
 
Heo et al., 
2015 60 
Korea 
Mixed definitions 
(e.g., spousal 
smoking or SHS 
exposure at home 
or workplace) 
Inc/Mort 128 M: 1.22 
W: 1.24 
SHS exposure in 
non-smokers. 
KNHANES 
Household 
member 
smoking at home 
and/or smell of 
tobacco smoke 
at workplace. 
KCHS 
At least 1 hour 
of exposure at 
home and/or 
smell of smoke 
for at least 1 
hour per day at 
workplace. 
KNHANES 
2005, 2007-
2010 117 ; 
KCHS118 
Men 
 Total:         22.2 
 20-29 y:     27.4 
 30-39 y:     36.9 
 40-49 y:     32.1 
 50-59 y:     25.5 
 60-69 y:     12.6 
 70+ y:          4.6 
Women 
 Total:         19.9 
 20-29 y:     22.5 
 30-39 y:     22.0 
 40-49 y:     28.2 
 50-59 y:     24.0 
 60-69 y:     13.9 
 70+ y:          8.3 
Men 
 Total:         4.7 
 20-29 y:     5.7 
 30-39 y:     7.5 
 40-49 y:     6.6 
 50-59 y:     5.3 
 60-69 y:     2.7 
 70+ y:        9.2 
Women 
 Total:         4.6 
 20-29 y:     5.1 
 30-39 y:     5.0 
 40-49 y:     6.3 
 50-59 y:     5.4 
 60-69 y:     3.2 
 70+ y:        2.0 
PAFs estimated by 
us from RR and % 
SHS exposure. 
Sung et al., 
2014 76 
Taiwan 
NA Mort 101 1.23 SHS exposure in 
non-smokers. 
Exposure at 
home or at 
workplace during 
the past week. 
National 
survey (Adult 
Smoking 
Behavior 
Survey) 
Total:          24.7 
Men:           24.1 
Woman:     25.2 
Total:          5.4 
Men:           5.3 
Women:     5.5 
PAFs estimated by 
us from RR and % 
SHS exposure. 
Yao et al., 
2015 44 
China 
NA NA 128-129 M:    1.24 
W:   1.22 
Participants 
living with a 
current smoker. 
National Rural 
Household 
Survey 
(NRHS) 
Men:           35.0 
Women:      62.2 
Men:             7 
Women:      13 
 
Zahra et al., 
2016 77 
Korea 
NA NA 120 20-29 y: 1.47 
30-34 y: 1.43 
35-39 y: 1.40 
40-44 y: 1.37 
45-49 y: 1.34 
50-54 y: 1.31 
55-59 y: 1.28 
60-64 y: 1.25 
65-69 y: 1.22 
70-74 y: 1.19 
75-79 y: 1.17 
≥80 y: 1.14 
SHS exposure in 
non-smokers. At 
home or 
workplace. 
KNHANES 
117 
Men 
 25-29 y:     41.7 
 30-34 y:     59.0 
 35-39 y:     56.4 
 40-44 y:     66.0 
 45-49 y:     59.0 
 50-54 y:     53.3 
 55-59 y:     53.5 
 60-64 y:     37.4 
 65-69 y:     27.5 
 70-74 y:     16.3 
 75-79 y:     17.9 
 ≥80 y:          5.2 
Women 
 25-29 y:     42.5 
 30-34 y:     23.3 
 35-39 y:     30.0 
 40-44 y:     30.0 
 45-49 y:     34.2 
 50-54 y:     34.3 
Men 
 25-29 y:      16 
 30-34 y:      20 
 35-39 y:      18 
 40-44 y:      20 
 45-49 y:      17 
 50-54 y:      14 
 55-59 y:      13 
 60-64 y:        8 
 65-69 y:        6 
 70-74 y:        3 
 75-79 y:        3 
 ≥80 y:           1 
Women 
 25-29 y:      17 
 30-34 y:        9 
 35-39 y:      11 
 40-44 y:      10 
 45-49 y:      10 
 50-54 y:        9 
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 55-59 y:     33.1 
 60-64 y:     23.2 
 65-69 y:     14.9 
 70-74 y:     16.2 
 75-79 y:       8.5 
 ≥80 y:          4.4 
 55-59 y:        8 
 60-64 y:        5 
 65-69 y:        3 
 70-74 y:        3 
 75-79 y:        1 
 ≥80 y:           1 
Zahra and 
Park, 2018 96 
Korea 
NA NA 120 25-29 y: 1.47  
30-34 y: 1.43 
35-39 y: 1.40 
40-44 y: 1.37 
45–49 y: 1.34 
50–54 y: 1.31 
55–59 y: 1.28 
60–64 y: 1.25 
65–69 y: 1.219 
70–74 y: 1.191 
75–79 y: 1.165 
80+ y: 1.139 
SHS exposure in 
nonsmokers at 
work or home 
KCHS118 6-35 25–29 y: 0.08.8 
30–34 y: 0.08.2 
35–39 y: 0.07.6 
40–44 y: 0.07.0 
45–49 y: 0.06.4 
50–54 y: 0.05.9 
55–59 y: 0.05.4 
60–64 y: 0.04.8 
65–69 y: 0.04.3 
70–74 y: 0.03.8 
75–79 y: 0.03.3 
≥80 y: 0.02.8 
PAFs estimated by 
us from RR and % 
SHS exposure 
(mean prevalence: 
20.5%). 
Africa 
Tachfouti et 
al., 2016 70 
Morocco 
NA NA 123 H: 1.30 
Wo: 1.21 
H&Wo: 1.30 
SHS exposure in 
never smokers. 
At home or at 
workplace. 
National 
survey 122 
At home only 
 Men 
  35-64 y:    20.0 
  ≥65 y:       15.1 
 Women 
  35-64 y:    38.4 
  ≥65 y:       25.0 
At work only 
 Men 
  35-64 y:    57.4 
Women 
  35-64 y:    25.5 
At home and work 
 Men 
  35-64 y:    25.3 
Women 
  35-64 y:    17.7 
At home only 
 Men 
  35-64 y:    5.7 
  ≥65 y:       4.3 
 Women 
  35-64 y:  10.3 
  ≥65 y:       7.0 
At work only 
 Men 
  35-64 y:  10.8 
Women 
  35-64 y:    5.1 
At home and work 
 Men 
  35-64 y:    7.1 
Women 
  35-64 y:    5.0 
Some PAFs 
estimated by us 
from RR and % 
SHS exposure 
 
COPD 
 
World 
GBD, 2017 26 
World 
NA NA IER curves 
for PM2.5 air 
pollution 
were used to 
estimate 
country-
specific RRs. 
NA SHS exposure in 
non-smokers. 
Exposure by a 
household 
member. 
NA NA Deaths:      4.1 
DALYs:       4.0 
 
Europe 
Fischer et al., 
2016 38 
Germany 
Mixed definitions 
(regular SHS 
exposure; e.g., 
spousal smoking 
or exposure to 20 
cigs/day) 
Inc/Mort 125 M: 1.50 
W: 2.17  
SHS exposure 
likely in non-
smokers. At any 
place, once per 
week or daily 
Own estimate 
from available 
data 126 
Men 
 18-29 y:     72.0 
 30-39 y:     49.0 
 40-49 y:     46.4 
 50-59 y:     42.5 
 60-69 y:     27.0 
 ≥70 y:        16.2 
Women 
 18-29 y:     61.6 
 30-39 y:     27.0 
 40-49 y:     28.1 
 50-59 y:     24.8 
 60-69 y:     17.0 
 ≥70 y:          8.9 
Men 
 18-29 y:   26.5 
 30-39 y:   19.7 
 40-49 y:   18.8 
 50-59 y:   17.5 
 60-69 y:   11.9 
 ≥70 y:        7.5 
Women 
 18-29 y:   41.9 
 30-39 y:   24.0 
 40-49 y:   24.7 
 50-59 y:   22.5 
 60-69 y:   16.6 
 ≥70 y:        9.4 
PAFs estimated by 
us from RR and % 
SHS exposure. 
Asia 
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Heo et al., 
2015 60 
Korea 
Lifetime home 
SHS exposure ≥42 
years 
Inc 130 1.55 SHS exposure in 
non-smokers. 
KNHANES 
Household 
member 
smoking at home 
and/or smell of 
tobacco smoke 
at workplace. 
KCHS 
At least 1 hour 
of exposure at 
home and/or 
smell of smoke 
for at least 1 
hour per day at 
workplace. 
KNHANES 
2005, 2007-
2010 117 ; 
KCHS 118 
Men:           22.2 
Women:      19.9 
Men:         10.9 
Women:     9.9 
 
Sung et al., 
2014 76 
Taiwan 
NA Inc 101 1.55 SHS exposure in 
non-smokers. 
Exposure at 
home or at 
workplace during 
the past week. 
National 
survey (Adult 
Smoking 
Behavior 
Survey) 
Total:          24.7 
Men:           24.1 
Woman:     25.2 
Total:        12.0 
Men:         11.7 
Women:   12.2 
PAFs estimated by 
us from RR and % 
SHS exposure. 
 
Stroke 
 
World 
Feigin et al., 
2016 88 
World 
  Meta-analysis 
of published 
studies. 
    2.2 (DALYs) Only PAF for 
DALYs was 
provided. 
GBD, 2016 25 
World 
NA NA IER curves 
were used to 
estimate 
country-
specific RRs. 
NA SHS exposure in 
non-smokers. 
Exposure by a 
household 
member. 
Various 
national and 
international 
surveys. 
NA Ischemic stroke 
Deaths:      2.4 
DALYs:     2.8 
 
Hemorrhagic 
stroke 
Deaths:      3.1 
DALYs:     3.5 
 
GBD, 2017 26 
World 
NA NA IER curves 
for PM2.5 air 
pollution 
were used to 
estimate 
country-
specific RRs. 
NA SHS exposure in 
non-smokers. 
Exposure by a 
household 
member. 
NA NA Ischemic stroke 
Deaths:      2.8 
DALYs:     3.0 
 
Hemorrhagic 
stroke 
Deaths:      3.2 
DALYs:     3.5 
 
Oceania 
Mason et al., 
2016 54 
New Zealand 
Spousal smoking 
or SHS exposure 
at home or at 
workplace 
Inc/Mort 131 1.25 SHS exposure in 
non-smokers. 
People smoking 
inside the 
respondent’s 
home and/or in 
the car they 
travelled in. 
New Zealand 
Health Surveys 
5.4 1.3 PAFs estimated by 
us from RR and % 
SHS exposure. 
Europe 
Heuschmann 
et al., 2007 61 
Germany 
NA Inc/Mort Pooled 
estimate 
from 132-133 
1.18 SHS exposure 
likely in non-
smokers. 
134 Men:           10.0 
Women:      13.6 
Men:           1.8 
Women:     2.4 
PAFs estimated by 
us from RR and % 
SHS exposure. 
Authors reported 
PAF in the overall 
population, 
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
 38 
including current 
smokers (0.9% in 
men and 1.5% in 
women). 
Fischer et al., 
2016 38 
Germany 
Mixed definitions 
(regular SHS 
exposure; e.g., 
spousal smoking 
or exposure to 20 
cigs/day) 
Inc/Mort 125 M: 1.40 
W: 1.43  
SHS exposure 
likely in non-
smokers. At any 
place, once per 
week or daily 
Own estimate 
from available 
data 126 
Men 
 18-29 y:     72.0 
 30-39 y:     49.0 
 40-49 y:     46.4 
 50-59 y:     42.5 
 60-69 y:     27.0 
 ≥70 y:        16.2 
Women  
 18-29 y:     61.6 
 30-39 y:     27.0 
 40-49 y:     28.1 
 50-59 y:     24.8 
 60-69 y:     17.0 
 ≥70 y:          8.9 
Men 
 18-29 y:   22.4 
 30-39 y:   16.4 
 40-49 y:   15.7 
 50-59 y:   14.5 
 60-69 y:     9.7 
 ≥70 y:        6.1 
Women  
 18-29 y:   20.9 
 30-39 y:   10.4 
 40-49 y:   10.8 
 50-59 y:     9.6 
 60-69 y:     6.8 
 ≥70 y:        3.7 
 
PAFs estimated by 
us from RR and % 
SHS exposure. 
Asia 
Heo et al., 
2015 60 
Korea 
Spousal smoking 
or SHS exposure 
at home or at 
workplace 
Inc/Mort 131 1.25 SHS exposure in 
non-smokers. 
KNHANES 
Household 
member 
smoking at home 
and/or smell of 
tobacco smoke 
at workplace. 
KCHS 
At least 1 hour 
of exposure at 
home and/or 
smell of smoke 
for at least 1 
hour per day at 
workplace. 
KNHANES 
2005, 2007-
2010 117 ; 
KCHS118 
Men:           22.2 
Women:      19.9 
Men:           5.3 
Women:     4.7 
 
Zahra et al., 
2016 77 
Korea 
NA NA 120 20-29 y: 1.59 
30-34 y: 1.54 
35-39 y: 1.49 
40-44 y: 1.45 
45-49 y: 1.41 
50-54 y: 1.36 
55-59 y: 1.32 
60-64 y: 1.28 
65-69 y: 1.25 
70-74 y: 1.21 
75-79 y: 1.18 
≥80 y: 1.15 
SHS exposure in 
non-smokers. At 
home or 
workplace. 
KNHANES 
117 
Men 
 25-29 y:     41.7 
 30-34 y:     59.0 
 35-39 y:     56.4 
 40-44 y:     66.0 
 45-49 y:     59.0 
 50-54 y:     53.3 
 55-59 y:     53.5 
 60-64 y:     37.4 
 65-69 y:     27.5 
 70-74 y:     16.3 
 75-79 y:     17.9 
 ≥80 y:          5.2 
Women 
 25-29 y:     42.5 
 30-34 y:     23.3 
 35-39 y:     30.0 
 40-44 y:     30.0 
 45-49 y:     34.2 
 50-54 y:     34.3 
 55-59 y:     33.1 
 60-64 y:     23.2 
 65-69 y:     14.9 
 70-74 y:     16.2 
 75-79 y:       8.5 
 ≥80 y:          4.4 
Men 
 25-29 y:      20 
 30-34 y:      24 
 35-39 y:      22 
 40-44 y:      23 
 45-49 y:      19 
 50-54 y:      16 
 55-59 y:      15 
 60-64 y:      10 
 65-69 y:        6 
 70-74 y:        3 
 75-79 y:        3 
 ≥80 y:           1 
Women 
 25-29 y:      20 
 30-34 y:      11 
 35-39 y:      13 
 40-44 y:      12 
 45-49 y:      12 
 50-54 y:      11 
 55-59 y:      10 
 60-64 y:        6 
 65-69 y:        4 
 70-74 y:        3 
 75-79 y:        1 
 ≥80 y:           1 
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Zahra and 
Park, 2018 96 
Korea 
NA NA 120 25–29 y: 1.59  
30–34 y: 1.541 
35–39 y: 1.493 
40–44 y: 1.448 
45–49 y: 1.405 
50–54 y: 1.362 
55–59 y: 1.322 
60–64 y: 1.283 
65–69 y: 1.246 
70–74 y: 1.211 
75–79 y: 1.177 
≥80 y: 1.145 
SHS exposure in 
nonsmokers at 
work or home 
KCHS 118 6-35 25–29 y: 0.10.8 
30–34 y: 0.10.0 
35–39 y: 0.09.2 
40–44 y: 0.08.4 
45–49 y: 0.07.7 
50–54 y: 0.06.9 
55–59 y: 0.06.2 
60–64 y: 0.05.5 
65–69 y: 0.04.8 
70–74 y: 0.04.1 
75–79 y: 0.03.5 
≥80 y: 0.02.9 
PAFs estimated by 
us from RR and % 
SHS exposure 
(mean prevalence: 
20.5%). 
 
Asthma 
 
World 
Oberg et al., 
2011 13 
World 
SHS exposure at 
home and 
workplace in the 
previous 12 
months 
Inc 135 1.97 
 
At home and/or 
at work. 
  11.6 (DALYs) Only PAF for 
DALYs was 
provided. 
North America 
Liu et al., 
2014 75 
USA 
SHS exposure at 
workplace in the 
previous 12 
months 
Inc 135 2.16 Percentage of 
servers not 
covered by 
smoke-free 
restaurants 
and/or bars. 
136 Restaurants: 22.8 
Bars:            29.6 
Total:        24.0 PAF for 
Minnesota only are 
also available 
Mason et al., 
2015 53 
USA 
SHS exposure at 
home and 
workplace in the 
previous 12 
months 
Inc 135 1.97 SHS exposure in 
non-smokers. 
Scenario 1: 
serum cotinine 
level ≥0.05 
ng/mL. 
Scenario 2: 
serum cotinine 
level ≥0.015 
ng/mL. 
NHANES Scenario 1 
 18-50 y:        48 
 51-64 y:        46 
 65-84 y:        38 
 ≥85 y:           38 
Scenario 2 
 18-50 y:        81 
 51-64 y:        79 
 65-84 y:        75 
 ≥85 y:           75 
Scenario 1 
 18-50 y:      32 
 51-64 y:      31 
 65-84 y:      27 
 ≥85 y:         27 
Scenario 2 
 18-50 y:      44 
 51-64 y:      43 
 65-84 y:      42 
 ≥85 y:         42 
 
Max et al., 
2015 49 
USA 
NA Inc 135 1.97 SHS exposure in 
non-smokers. 
Living in a house 
where someone 
smokes inside at 
least 1 day per 
week. 
CHIS 5.01 4.6  
Europe 
Schram-
Bijekerk et 
al., 2013 63 
The 
Netherlands 
SHS exposure at 
home and 
workplace in the 
previous 12 
months 
Inc 135 1.97 SHS exposure in 
non-smokers. 
Daily exposure. 
113 18-40 (mean: 29) 22.0  
Rumrich et 
al., 2015 62 
Finland 
SHS exposure at 
home and 
workplace in the 
previous 12 
months 
Inc 135 1.97 Exposure to 
SHS in never 
smokers. 
Exposure during 
past 12 months 
at home or at 
workplace. 
135 10 8.8 PAFs estimated by 
us from RR and % 
SHS exposure. 
Asia 
Heo et al., 
2015 60 
Korea 
SHS exposure at 
home and 
workplace in the 
Inc 135 1.97 SHS exposure in 
non-smokers. 
KNHANES 
KNHANES 
2005, 2007-
2010 117 ; 
Men:           22.2 
Women:      19.9 
Men:         17.7 
Women:   16.2 
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previous 12 
months 
Household 
member 
smoking at home 
and/or smell of 
tobacco smoke 
at workplace. 
KCHS 
At least 1 hour 
of exposure at 
home and/or 
smell of smoke 
for at least 1 
hour per day at 
workplace. 
KCHS118 
Sung et al., 
2014 76 
Taiwan 
SHS exposure at 
home and 
workplace in the 
previous 12 
months 
Inc 135 1.97 SHS exposure in 
non-smokers. 
Exposure at 
home or at 
workplace during 
the past week. 
National 
survey (Adult 
Smoking 
Behavior 
Survey) 
Total:          24.7 
Men:           24.1 
Woman:     25.2 
Total:        19.3 
Men:         18.9 
Women:   19.6 
PAFs estimated by 
us from RR and % 
SHS exposure. 
Yao et al., 
2015 61 
China 
SHS exposure at 
home and 
workplace in the 
previous 12 
months 
Inc 135 1.97 Participants 
living with a 
current smoker. 
National Rural 
Household 
Survey 
(NRHS) 
Men:           35.0 
Women:      62.2 
Men:           25 
Women:      38 
 
 
Breast cancer 
 
World 
GBD, 2017 26 
World 
NA NA From 
published 
meta-
analyses. 
1.07 SHS exposure in 
non-smokers. 
Exposure by a 
household 
member. 
NA NA 1.9  
North America 
Max et al., 
2015 49 
USA 
NA Inc 101 1.68 SHS exposure in 
non-smokers. 
Living in a house 
where someone 
smokes inside at 
least 1 day per 
week. 
CHIS 3.1 2.1  
Europe 
Gram et al., 
2016 22 
Norway 
NA Incidence Original 1.18 SHS exposure in 
never smokers. 
NA 
Original 64.8 10.4 PAF estimated by 
us from RR and % 
SHS exposure 
among never 
smokers. 
Asia 
Yao et al., 
2015 44 
China 
NA NA 138 1.60 Participants 
living with a 
current smoker. 
National Rural 
Household 
Survey 
(NRHS) 
62.2 27  
 
Diabetes 
 
World 
GBD, 2017 26 
World 
NA NA From 
published 
meta-
analyses. 
1.34 SHS exposure in 
non-smokers. 
Exposure by a 
household 
member. 
NA NA 6.6  
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* Inc: Incidence; Mort: mortality; DALY: DALYs; NA: not available 
^ M: men; W: women; H: home; Wo: work 
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Table 4 – Proportion attributable fraction (PAF) estimates due to second-hand smoke (SHS) among 
children for selected diseases, sorted by disease, continent (world, North America, Oceania, Europe, 
Asia and Africa), year of publication and author name. 
Study 
Country 
RR SHS exposure PAF 
(%) 
Notes 
Definition Endpoint* Source RR Definition Source % 
 
Otitis media 
 
World 
Öberg et al., 
2011 13 
World 
 
Children aged 
<3 years with 
serum cotinine 
concentration 
greater than or 
equal to 2.5 
ng/mL (otitis 
media with 
effusion) 
Inc 101,139 1.38  Children having one or 
both parents who 
smoke or being exposed 
to tobacco smoke or to a 
person who smokes 
indoors 
Various 
national and 
multinational 
Surveys 
(mainly Global 
Youth 
Tobacco 
Smoking 
(GYTS):13-15 
years) 
NA 1.7 (DALYs) Only PAF for 
DALYs was 
provided. 
GBD, 2016 25 
World 
Children 
exposed to  
household 
smoking 
(middle ear 
infection and 
surgery for 
middle ear 
disease) 
Inc 140 1.37  Children aged < 5 years 
exposed to any tobacco 
smoke inside the home 
Various 
national and 
international 
surveys 
NA 5.4    
GBD, 2017 26 
World 
Children 
exposed to  
household 
smoking 
(middle ear 
infection and 
surgery for 
middle ear 
disease) 
Inc 140 1.37  Children aged <14 years 
exposed to tobacco 
smoke by a household 
member, (household 
composition as proxy for 
exposure/ assumption 
that all persons living with 
a smoker are exposed to 
smoke) 
Various 
national and 
international 
surveys 
NA 3.5 
 
 
North America 
Waters et al., 
2009 37 
USA 
   Not 
used 
  Not used 14.0 Non original PAF, 
from 98 
Mason et al., 
2015 53 
USA 
Children aged 
< 4 years 
exposed to 
SHS fro either 
parent (middle 
ear effusion) 
Inc 2 1.33  Cotinine level greater than 
0.05 / 0.015 ng/mL 
measured in children aged 
3-11 (assumed also for 
children  
aged < 3 years) 
National 
NHANES 
0.05 ng/mL: 61  
0.015 ng/mL: 85 
0.05 ng/mL: 17.2 
0.015 ng/mL: 22.4 
 
Max et al., 2015 
49 
USA 
Children aged 
<3 years with 
serum cotinine 
concentration 
greater than or 
equal to 2.5 
ng/mL (otitis 
media with 
effusion) 
Inc 101,139 1.38  Children aged <3 years 
who live in households 
that allow smoking and 
where smoking is 
reported to occur some 
days or every day 
CHIS to 
children (<12 
years) and 
adolescents 
(12-17 years) 
2.44 (1.64,3.25) 0.9  
Oceania 
Mason et al., 
2016 54 
New Zealand 
 
Children 
exposed to  
household 
smoking 
(middle ear 
Inc 140 1.32  Children exposed to SHS 
in home and car: surveyed 
adults declaring that 
anyone smokes inside 
their home and/or in the 
New Zealand 
Health Surveys 
8.7 2.7 PAFs estimated by 
us from RR and % 
SHS exposure 
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Study 
Country 
RR SHS exposure PAF 
(%) 
Notes 
Definition Endpoint* Source RR Definition Source % 
infection) car their child travelled in 
Europe 
Royal College of 
Physicians, 2010 
23 
UK 
Children 
exposed to 
household 
smoking 
(middle ear 
disease) 
Inc Meta-analysis 
in 23 
1.35  Children aged 4-15 years 
not living in a smoke-free 
home 
Health Survey 
for England 
(HSE) 
22 7.1  
Schram-Bijkerk 
et al., 2013 63 
The Netherlands 
Children aged 
<3 years with 
serum cotinine 
concentration 
greater than or 
equal to 2.5 
ng/mL (otitis 
media with 
effusion) 
Inc 101,139 1.38  Children aged 0-4 years 
being exposed to tobacco 
smoke at home 
112 28 
 
9.6 (4.0,16.8)  
Jarosińska et al., 
2014 97 
Poland 
Children aged 
<3 years with 
serum cotinine 
concentration 
greater than or 
equal to 2.5 
ng/mL (otitis 
media with 
effusion) 
Inc 101,139 1.38  Children exposed to any 
tobacco smoke: 
Scenario 1: surveyed 
adults admitted to 
smoking/having smoked 
in the presence of their 
children  
Scenario 2: children aged 
13-15 years exposed in 
households and public 
place 
Scenario 1: 
national survey 
Scenario 2: 
GYTS 
Scenario 1: 48 
Scenario 2: 60 
Scenario 1: 15.4 
Scenario 2: 18.6 
 
 
SIDS 
 
North America 
Behm et al., 2012 
20 
USA 
Children aged 
<1 year 
exposed to 
postnatal 
maternal 
smoking 
Mort 23 3.15 Households with at least 
one infant and a rule 
disallowing smoking 
anywhere in the home 
Tobacco use 
Supplement to 
the Current 
Population 
Survey 
1995: 35.9  
2006: 11.7  
1995:  43.6  
2006:  20.1 
 
Max et al., 2012 
52 
USA 
Children 
exposed to 
maternal 
smoking 
during 
pregnancy 
Mort 141 2.29 Infant exposure to 
maternal smoking in utero 
Data from 
birth 
certificates 142  
13.2 14.6 PAFs estimated by 
us from RR and % 
SHS exposure 
Mason et al., 
2015 53 
USA 
Children aged 
<1 year 
exposed to 
postnatal 
maternal 
smoking 
Mort 143 1.94 Cotinine level >0.05 / 
0.015 ng/mL measured in 
children aged 3-11 
(assumed for children  
aged < 3 years) 
NHANES 0.05 ng/mL: 48  
0.015 ng/mL: 81  
0.05 ng/mL: 31.1 
0.015 ng/mL: 43.2 
 
Max et al., 2015 
49 
USA 
Children 
exposed to 
maternal 
smoking 
during 
pregnancy 
Mort 141 2.29 Infant exposure to 
maternal smoking in utero 
Maternal and 
Infant Health 
Assessment 
survey 
5.6 6.7  
Oceania 
Mason et al., 
2016 54 
New Zealand 
Children aged 
<1 year 
exposed to 
Mort 143 1.94  Mothers with newborns 
smoking at two weeks 
after birth 
Nationwide 
Well 
Child/Tamarik
13 10.9 PAFs estimated by 
us from RR and % 
SHS exposure 
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Study 
Country 
RR SHS exposure PAF 
(%) 
Notes 
Definition Endpoint* Source RR Definition Source % 
postnatal 
maternal 
smoking 
iOra health 
checks 
programme for 
infants 
Europe 
Jarosińska et al., 
2014 97 
Poland 
Children aged 
<1 year 
exposed to 
postnatal 
maternal 
smoking 
Mort 143 1.94  Smoking women aged 
20–39 years 
Global Adult 
Tobacco 
Smoking 
(GATS) 
26 19.6 
 
 
Royal College of 
Physicians, 2010 
23  
UK 
Children aged 
<1 year 
exposed to 
household 
exposure 
Mort Meta-analysis 
in 23 
2.31 Children aged 4-15 years 
not living in a smoke-free 
home 
Health Survey 
for England 
(HSE) 
22 22.4  
Schram-Bijkerk 
et al., 2013 63 
The Netherlands 
Children aged 
<1 year 
exposed to 
postnatal 
maternal 
smoking 
Mort 143 1.94  Children aged 0-4 years 
being exposed to tobacco 
smoke at home 
113 28 20.8 (9.9,34.0)  
 
LRI 
 
World 
Öberg et al., 
2011 13 
world 
Children aged 
0-3 years 
exposed to 
SHS from 
either parent 
Inc 2 1.55  Children having one or 
both parents who 
smoke or being exposed 
to tobacco smoke or to a 
person who smokes 
indoors 
Various 
national and 
multinational 
surveys (mainly 
GYTS: 13-15 
years) 
NA 6.3 (DALYs) Only PAF for 
DALYs was 
provided. 
GBD, 2016 25 
World 
NA NA IER curves 
were used to 
estimate 
country-
specific RRs. 
NA Children aged < 5 years 
exposed to any tobacco 
smoke inside the home 
Various 
national and 
international 
surveys 
NA 6.7    
GBD, 2017 26 
World 
NA NA IER curves 
were used to 
estimate 
country-
specific RRs. 
NA People of all ages years 
exposed to tobacco 
smoke by a 
household member, 
(household composition 
as proxy for exposure/ 
assumption 
that all persons living with 
a smoker are exposed to 
smoke) 
Various 
national and 
international 
surveys 
NA 5.8   
North America 
Mason et al., 
2015 53 
USA 
Children aged 
0-3 years 
exposed to 
SHS from 
either parent 
Inc 2 1.55  Cotinine level >0.05 / 
0.015 ng/mL measured in 
children aged 3-11 
(assumed for children  
aged < 3 years) 
NHANES 0.05 ng/mL: 61 
0.015 ng/mL: 85 
0.05 ng/mL: 25.1 
0.015 ng/mL: 31.9 
 
 
Max et al., 2015 
49 
USA 
Children aged 
0-2 years 
exposed to 
parental 
smoking 
Inc 101 1.75  Children aged <2 years 
who live in households 
that allow smoking and 
where smoking is 
reported to occur some 
days or every day 
CHIS to 
children (<12 
years) and 
adolescents 
(12-17 years) 
2.70 (1.77,3.62) 2.0  
Oceania 
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Study 
Country 
RR SHS exposure PAF 
(%) 
Notes 
Definition Endpoint* Source RR Definition Source % 
Mason et al., 
2016 54 
New Zealand 
Children aged 
0-2 years 
exposed to 
SHS by any 
household 
member 
NA 140 1.54  Children exposed to SHS 
in home and car: surveyed 
adults declaring that 
anyone smokes inside 
their home and/or in the 
car their child travelled in 
New Zealand 
Health Surveys 
8.7 4.5 PAFs estimated by 
us from RR and % 
SHS exposure 
Europe 
Royal College of 
Physicians, 2010 
23 
UK 
Children 
exposed to 
household 
smoking 
Inc Meta-analysis 
in 23 
1.54  Children aged 4-15 years 
not living in a smoke-free 
home 
Health Survey 
for England 
(HSE) 
22 10.6  
Schram-Bijkerk 
et al., 2013 63 
The Netherlands 
Children aged 
0-2 years 
exposed to 
SHS from 
either parent 
NA 2 1.55  Children aged 0-4 years 
being exposed to tobacco 
smoke at home 
113 28 
 
13.3 (7.8,19.9)  
Jarosińska et al., 
2014 97 
Poland 
Children aged 
0-3 years 
exposed to 
SHS from 
either parent 
Inc 2 1.55 Children exposed to any 
tobacco smoke: 
Scenario 1: surveyed 
adults admitted to 
smoking/having smoked 
in the presence of their 
children  
Scenario 2: children aged 
13-15 years exposed in 
households and public 
place 
Scenario 1: 
national survey 
Scenario 2: 
GYTS  
Scenario 1: 48 
Scenario 2: 60 
exposed in 
households/public 
place 
Scenario 1:  20.9 
Scenario 2:  24.8 
 
 
Asthma induction 
 
World 
Öberg et al., 
2011 13 
world 
Children aged 
0-14 years 
exposed to 
SHS from 
either parent 
Inc 101 1.32  Children having one or 
both parents who 
smoke or being exposed 
to tob cco smoke or to a 
person who smokes 
indoor 
Various 
national and 
multinational 
surveys (mainly 
GYTS:13-15 
years) 
NA 1.6 (DALYs) Only PAF for 
DALYs was 
provided. 
North America 
Waters et al., 
2009 37 
USA 
  2 1.23 NA Minnesota 
Department of 
Health 
not known 35 Non original PAF, 
from Zollinger et 
al., 2004 
Simons et al., 
2011 79 
Canada 
Children aged 
0-5 years 
exposed to 
maternal 
smoking 
during 
pregnancy 
Inc 144-145 1.40 NA Websites of 
government 
agencies and 
published 
studies 
9.0 3.5 PAFs estimated by 
us from RR and % 
SHS exposure. 
Age-specific PAF 
estimate reported 
is reported in the 
paper: 
0-5 years: 2.9 
6-11 years: 3.1 
Mason et al., 
2015 53 
USA 
Children aged 
1-17 years 
exposed to 
SHS by 
parental report 
or by cotinine 
measurement 
Inc 146 1.32  - Children aged 1-11 
years: cotinine level >0.05 
/ 0.015 ng/mL (measured 
in children aged 3-11 
assumed also for children  
aged < 3 years) 
- Children 12-19 years: 
reporting no smoking in 
the previous 30 days, no 
use of any nicotine-
NHANES 0.05 ng/mL: 61  
0.015ng/mL: 85  
0.05 ng/mL: 16.3 
0.015ng/mL: 21.4 
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Study 
Country 
RR SHS exposure PAF 
(%) 
Notes 
Definition Endpoint* Source RR Definition Source % 
containing product within 
the previous 5 days  and a 
serum cotinine level > 
0.05 /0.015 ng/mL. 
Max et al., 2015 
49 
USA 
Children aged 
0-14 years 
exposed to 
SHS from 
either parent 
Inc 101 1.32  Children who live in 
households that allow 
smoking and where 
smoking is 
reported to occur some 
days or every day 
CHIS to 
children (<12 
years) and 
adolescents 
(12-17 years) 
0-11 years: 2.63 
(2.24,3.02)  
12-17 years: 3.81 
(3.21,4.42) 
0-11 years: 0.8 
12-17 years: 1.2 
 
Oceania 
Mason et al., 
2016 54 
New Zealand 
 
Children aged 
1-17 years 
exposed to 
SHS by 
parental report 
or by cotinine 
measurement 
Inc 146 1.32  Children exposed to SHS 
in home and car: surveyed 
adults declaring that 
anyone smokes inside 
their home and/or in the 
car their child travelled in 
New Zealand 
Health Surveys 
8.7 2.7 PAFs estimated by 
us from RR and % 
SHS exposure 
Europe 
Royal College of 
Physicians, 2010 
23 
UK 
Children aged 
3-4 and 5-16 
years exposed 
to household 
smoking 
Inc Meta-analysis 
in 23 
3-4 
years: 
1.21 
5-16 
years: 
1.50  
Children aged 4-15 years 
not living in a smoke-free 
home 
Health Survey 
for England 
(HSE) 
22 3-4 years: 4.4 
5-16 years: 9.9 
 
Schram-Bijkerk 
et al., 2013 63 
The Netherlands 
Children aged 
0-14 years 
exposed to 
SHS from 
either parent 
Inc 101 1.32  Children aged 0-4 years 
being exposed to tobacco 
smoke at home 
113 28 8.2 (4.6, 12.9)  
Jarosińska et al., 
2014 97 
Poland 
Children aged 
0-14 years 
exposed to 
SHS from 
either parent 
Inc 101 1.32  
 
Children exposed to any 
tobacco smoke: 
Scenario 1: surveyed 
adults admitted to 
smoking/having smoked 
in the presence of their 
children  
Scenario 2: children aged 
13-15 years exposed in 
households and public 
place 
Scenario 1: 
national survey  
Scenario 2: 
GYTS 
Scenario 1: 48 
Scenario 2: 60  
Scenario 1: 13.3 
Scenario 2: 16.1 
 
Rumrich et al., 
2015 62 
Finland 
Children aged 
0-14 years 
exposed to 
SHS from 
either parent 
Inc 101 1.32  Children aged 15 years 
and over regularly 
exposed to SHS or having 
at least one smoking 
parent 
147 4 1.3 PAFs estimated by 
us from RR and % 
SHS exposure 
Asia 
Tabuchi et al., 
2015 21 
Japan 
Children aged 
0-8 years 
exposed to 
parental 
indoor 
smoking 
Inc Estimated in 
nationally a 
representativ
e population-
based birth 
cohort  
0-2.5 
years: 
1.54 
 
2.5−4.5
years: 
1.43 
 
4.5−8 
years: 
1.72 
Children aged 0-5 years 
exposed to parental 
indoor smoking 
Estimated in 
nationally a 
representative 
population-
based birth 
cohort 
10.9 0-2.5 years: 5.6 
2.5-4.5 years: 4.5 
4.5-8 years: 7.3 
We consider only 
both parental 
indoor smoking 
(see corresponding 
appendix of 21) 
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Study 
Country 
RR SHS exposure PAF 
(%) 
Notes 
Definition Endpoint* Source RR Definition Source % 
 
North America 
Max et al., 2012 
52 
USA 
Children 
exposed to 
maternal 
smoking 
during 
pregnancy 
Mort 141 1.83 Infant exposure to 
maternal smoking In 
utero 
Data from 
birth 
certificates 142  
13.2 9.9 PAFs estimated by 
us from RR and % 
SHS exposure 
Mason et al., 
2015 53 
USA 
Children aged 
0 years with 
non-smoking 
mother ever 
exposed to 
SHS at work 
or at home  
Inc 148 1.38 Non-smoking women 
with cotinine level >0.05 
/ 0.015 ng/mL 
NHANES 0.05 ng/mL: 48  
0.015 ng/mL: 81 
0.05 ng/mL: 15.4 
0.015 ng/mL: 23.5 
 
Max et al., 2015 
49 
USA 
Children aged 
0 years with 
non-smoking 
mother ever 
exposed  to 
SHS at work 
or at home  
Inc 148 1.38 Smoking pregnant women Maternal and 
Infant Health 
Assessment 
survey 
5.6 (4.90,6.40) 2.1 
 
 
Oceania 
Mason et al., 
2016 54 
New Zealand 
Children aged 
0 years with 
non-smoking 
mother ever 
exposed to 
SHS at work 
or at home  
Inc 148 1.38  Non-smoking pregnant 
women who had a partner 
who smoked 
Antenatal 
interview in 
the “Growing 
Up in New 
Zealand” 
longitudinal 
study  
 
 7.0 (6.3,7.6) 2.6 
  
PAFs estimated by 
us from RR and % 
SHS exposure 
Europe 
Jarosińska et al., 
2014 97 
Poland 
Children aged 
0 years with 
non-smoking 
mother ever 
exposed to 
SHS at work 
or at home  
Inc 148 1.38 Adults admitting to 
smoke in the presence of 
pregn nt women and 
non-smoking women 
aged 20-45 years exposed 
to SHS at home 
149 27 9.3  
* Inc: Incidence; Mort: mortality; DALY: DALYs; NA: not available 
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Figure 1 – PRISMA flow chart of publications (01/01/2007-31/12/2018) included in the systematic review. 
 
Papers from the 
literature search in 
PubMed  
(n=280)  
 
Papers from the 
literature search in 
SCOPUS  
(n=564) 
)  
 
Duplicates (n=256) 
 
Articles screened on the basis of abstract (n=482) 
 
Excluded (n=106): 
106 (18%) clearly not on 
SHS or burden 
Excluded (n=388): 
137 (35%) reviews or other studies 
not reporting original results; 
83 (21%) on RRs estimates; 
55 (14%) on the prevalence of SHS 
exposure or of SHS-related 
diseases;  
58 (15%) not on SHS or burden;  
55 (14%) on animals/cells, methods 
to measure or model exposure, 
policies evaluation, meta-analyses 
on RRs.  
 
Added from reference 
lists (n=4) 
 
Excluded (n=22): 
22 (23%) not estimating the 
burden on disease due to 
SHS exposure  
 
 Manuscript included (n=72) 
 
Articles screened on the basis of title (n=588) 
 
Manuscript reviewed (n=94) 
 
n=844 
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Highlights 
 Burden of disease from second-hand smoke was not studied for all worldwide areas  
 Not all diseases with the strongest evidence of causation were assessed 
 Burden is estimated applying risks and exposures with not consistent definitions  
 The population attributable fractions are largely variable among studies     
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